J Korean Neuropsychiatr Assoc.  2019 Feb;58(1):2-11. 10.4306/jknpa.2019.58.1.2.

History and Future of Antipsychotic Drugs

• Yi JS

• KMID: 2439022
• DOI: http://doi.org/10.4306/jknpa.2019.58.1.2

Abstract

After the discovery of antipsychotic drugs, the nature of clinical practice entered a period of inexorable transition. The advances of psychopharmacotherapy have interacted in complex ways with clinical practice, and the economics and policy of mental health care systems. The study of the mechanisms of action of these drugs has guided the development of hopefully improved treatment, and stimulated biological research on the pathophysiology of severe mental disorders. Despite the considerable effort to modify and change existing antipsychotic drugs, progress has been modest. This review describes the history of antipsychotic drugs and their impact on clinical practice and the study of psychiatric disorders, and offer prospects for future developments. Although finding new knowledge and methodologies to bring innovative discovery is imperative, as of now, it is important to provide comprehensive care, including the optimal use of existing antipsychotic drugs.

Keyword

First-generation antipsychotics; Second-generation antipsychotics; History; Future

MeSH Terms

Antipsychotic Agents*
Mental Disorders
Mental Health
Antipsychotic Agents

Reference

1. Ahonen M. Mental Disorders in Ancient Philosophy. Switzerland: Spinger International Publishing;2014. p. 28–29.

2. Baumeister AA, Hawkins MF. Continuity and discontinuity in the historical development of modern psychopharmacology. J Hist Neurosci. 2005; 14:199–209.

3. Baldessarini RJ. [Commentary: the current state of psychopharmacology and psychiatry.]. Rev Psiquiatr Salud Men. 2011; 4:5–8.

4. Lehmann HE. Before they called it psychopharmacology. Neuropsychopharmacology. 1993; 8:291–303.

5. Lehmann HE, Ban TA. The history of the psychopharmacology of schizophrenia. Can J Psychiatry. 1997; 42:152–162.

6. Luigjes J, de Kwaasteniet BP, de Koning PP, Oudijn MS, van den Munckhof P, Schuurman PR, et al. Surgery for psychiatric disorders. World Neurosurg. 2013; 80:S31.e17–S31.e28.

7. Robison RA, Taghva A, Liu CY, Apuzzo ML. Surgery of the mind, mood, and conscious state: an idea in evolution. World Neurosurg. 2013; 80:S2–S26.

8. López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005; 17:113–135.

9. Kunz E. Henri Laborit and the inhibition of action. Dialogues Clin Neurosci. 2014; 16:113–117.

10. Hamon J, Paraire J, Velluz J. [Effect of R. P. 4560 on maniacal agitation]. Ann Med Psychol (Paris). 1952; 110:331–335.

11. Carpenter WT Jr, Davis JM. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatry. 2012; 17:1168–1173.

12. Lehmanne HE, Hanrahan GE. Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states. Arch Neurol Psychiatry. 1954; 71:227–237.

13. Delay J, Deniker P. Chlorpromazine and neuroleptic treatments in psychiatry. J Clin Exp Psychophatol. 1956; 17:19–24.

14. Delay J, Deniker P. Cas de psychoses traitées par la cure prolongée et continue de 4560 RP. CR 50e Congrès des aliénistes et neurol. de Langue Fse. 1952; 38:503–513.

15. Moncrieff J. An investigation into the precedents of modern drug treatment in psychiatry. Hist Psychiatry. 1999; 10:475–490.

16. Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005; 17:137–140.

17. Divry P, Bobon J, Collard J. Le R1625, nouvelle thérapeutique symptomatique de l'agitation psychomotrice. Acta Neurol Psychiatr Belg. 1958; 58:878–888.

18. Divry P, Bobon J, Collard J. [Report on the neuropsycho-pharmacological activity of haloperidol (R 1625)]. Acta Neurol Psychiatr Belg. 1960; 60:7–19.

19. Divry P, Bobon J, Collard J, Pinchard A, Nols E. [Study & clinical trial of R 1625 or haloperidol, a new neuroleptic & so-called neurodysleptic agent]. Acta Neurol Psychiatr Belg. 1959; 59:337–366.

20. Deniker P. Experimental neurological syndromes and the new drug therapies in psychiatry. Compr Psychiatry. 1960; 1:92–102.

21. Moncrieff J. Magic bullets for mental disorders: the emergence of the concept of an “antipsychotic” drug. J Hist Neurosci. 2013; 22:30–46.

22. Hasse HJ. [Definition and mode of action of the psychomotor Parkinson syndrome therapeutically induced by serpasil and largactil]. Monatsschr Psychiatr Neurol. 1956; 131:201–214.

23. Haase HJ, Janssen PAJ. The Action of Neuroleptic Drugs: a Psychiatric, Neurologic and Pharmachological Investigation. Chicago: Yearbook Medical Publishers;1965.

24. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses]. Ann Med Psychol (Paris). 1960; 118:145–152.

25. Guttmacher MS. Phenothiazine treatment in acute schizophrenia; effectiveness: The National Institute of Mental Health, Psychopharmacology Service Center, Collaborative Study Group. Arch Gen Psychiatry. 1964; 10:246–261.

26. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382:951–962.

27. Tandon R. Antipsychotic treatment of schizophrenia: two steps for ward, one step back. Curr Psychiatry Rep. 2007; 9:263–264.

28. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007; 18:39–60.

29. Pisciotta AV, Ebbe S, Lennon EJ, Metzger GO, Madison FW. Agranulocytosis following administration of phenothiazine derivatives. Am J Med. 1958; 25:210–223.

30. Anderman B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol. 1977; 11:199–201.

31. Amsler HA, Teerenhovi L, Barth E, Harjula K. Agranulocytosis in patients treated with Clozaril. A study of the Finnish epidemic. Acta Psychiatr Scand. 1977; 56:241–248.

32. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenics. Psychopharmacol Bull. 1988; 24:62–67.

33. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004; 3:353–359.

34. Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017; 14:750–761.

35. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988; 244:685–693.

36. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and Serotonin2 pKi values. J Pharmacol Exp Ther. 1989; 251:238–246.

37. Rebec GV, Bashore TR, Zimmerman KS, Alloway KD. “Classical” and “atypical” antipsychotic drugs: differential antagonism of amphetamine-and apomorphine-induced alterations of spontaneous neuronal activity in the neostriatum and nucleus accumbens. Pharmacol Biochem Behav. 1979; 11:529–538.

38. Meltzer HY, Bastani B, Ramirez L, Matsubara S. Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci. 1989; 238:332–339.

39. Casey AB, Canal CE. Classics in Chemical Neuroscience: aripiprazole. ACS Chem Neurosci. 2017; 8:1135–1146.

40. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995; 274:329–336.

41. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16:488–501.

42. McEvoy J, Citrome L. Brexpiprazole for the treatment of schizophrenia: a review of this novel serotonin-dopamine activity modulator. Clin Schizophr Relat Psychoses. 2016; 9:177–186.

43. Citrome L. Cariprazine for the treatment of schizophrenia: a review of this dopamine D3-preferring D3/D2 receptor partial agonist. Clin Schizophr Relat Psychoses. 2016; 10:109–119.

44. Kumar B, Kuhad A, Kuhad A. Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs Today (Barc). 2018; 54:713–719.

45. Min SK. The past, present and future of psychopharmacology in Korea. Clin Psychopharmacol Neurosci. 2006; 4:11–23.

46. Bahk WM, Lee HS. Chapter 1. Historical overview of Psychopharmacology. In : Bahk WM, Kim CH, editors. Clinical Neuropsychopharmacology. 2nd ed. Seoul: Sigma Press;2014. p. 3–11.

47. Delay J, Deniker P. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. Int Rec Med Gen Pract Clin. 1955; 168:318–326.

48. King C, Voruganti LN. What's in a name? The evolution of the nomenclature of antipsychotic drugs. J Psychiatry Neurosci. 2002; 27:168–175.

49. González Monclús E. Tratamientos farmacológicos y biológicos en los inicios de la clínica psiquiátrica universitaria del Profesor Sarró. In : Anton P, editor. coord. Medio Siglo de Psiquiatría en España. Madrid: ELA;1992. p. 81–83.

50. Lehmann HE. Concepts, rationale and research. In : Kline NS, editor. Psychopharmacology frontiers: second international congress of psychiatry psychopharmacology symposium. London: J & A Churchill Ltd;1959. p. 21–30.

51. Mapp Y, Nodine JH. Psychopharmacology: II tranquilizers and antipsychotic drugs. Psychosomatics. 1962; 3:458–463.

52. Macaluso M, Flynn A, Preskorn SH. Tardive dyskinesia: a historical perspective. J Psychiatr Pract. 2017; 23:121–129.

53. Schonecker M. [Paroxysmal dyskinesia as the effect of megaphen]. Nervenarzt. 1957; 28:550–553.

54. Kirkby KC. Social context and health consequences of the antipsychotics introduction. Ann Clin Psychiatry. 2005; 17:141–146.

55. Shepherd M. Neurolepsis and the psychopharmacological revolution: myth and reality. Hist Psychiatry. 1994; 5:89–96.

56. Bennett D. The drive towards the community. In : Berrios GE, Freeman H, editors. 150 years of British Psychiatry, 1841-1991. London: Gaskell/Royal College of Psychiatrists;1991. p. 321–332.

57. DeGrandpre R. The cult of pharmacology: how America became the world's most troubled drug culture. Durham, NC: Duke University Press;2006.

58. Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy PA, Favre J, Simon N, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015; 21:3280–3297.

59. Wikipedia. [homepage on the Internet]. List of off-label promotion pharmaceutical settlements. San Francisco, CA: Wikimedia Foundation;Available from: https://en.wikipedia.org/wiki/List_of_off-label_promotion_pharmaceutical_settlements.

60. Dean CE. Psychopharmacology: a house divided. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35:1–10.

61. Carpenter WT Jr, Kirkpatrick B. The heterogeneity of the long-term course of schizophrenia. Schizophr Bull. 1988; 14:645–652.

62. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Publishing;2013.

63. Frances A, Mack AH, Ross R, First MB. The DSM-IV classification and psychopharmacology. In : Bloom FE, Kupfer DJ, editors. Psychopharmacology the fourth generation of progress. New York: Raven Press, Ltd.;1995. p. 823.

64. Taylor MA, Vaidya NA. Psychopathology in neuropsychiatry: DSM and beyond. J Neuropsychiatry Clin Neurosci. 2005; 17:246–249.

65. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry. 1975; 132:1237–1245.

66. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012; 379:2063–2071.

67. Remington G, Fervaha G, Foussias G, Agid O, Turrone P. Antipsychotic dosing: found in translation. J Psychiatry Neurosci. 2014; 39:223–231.

68. Depp C, Lebowitz BD. Clinical trials: bridging the gap between efficacy and effectiveness. Int Rev Psychiatry. 2007; 19:531–539.

69. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh). 1963; 20:140–144.

70. van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther. 1966; 160:492–494.

71. Eisenberg L. Mindlessness and brainlessness in psychiatry. Br J Psychiatry. 1986; 148:497–508.

72. Bracken P, Thomas P, Timimi S, Asen E, Behr G, Beuster C, et al. Psychiatry beyond the current paradigm. Br J Psychiatry. 2012; 201:430–434.

73. Olfson M, Weissman MM, Gottlieb JF. Essential roles for psychiatry in the era of managed care. Arch Gen Psychiatry. 1997; 54:206–208.

74. Kondej M, Stępnicki P, Kaczor AA. Multi-target approach for drug discovery against schizophrenia. Int J Mol Sci. 2018; 19:E3105.

75. Dauvermann MR, Lee G, Dawson N. Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research. Br J Pharmacol. 2017; 174:3136–3160.

76. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012; 17:1206–1227.

77. International Schizophrenia Consortium. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009; 460:748–752.

78. Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology. 2018; 142:41–62.

79. Nikiforuk A. Assessment of cognitive functions in animal models of schizophrenia. Pharmacol Rep. 2018; 70:639–649.

80. Preissmann D, Dépré M, Schenk F, Gisquet-Verrier P. Anxiety modulates cognitive deficits in a perinatal glutathione deficit animal model of schizophrenia. Brain Res. 2016; 1648:459–468.

81. Forray C, Buller R. Challenges and opportunities for the development of new antipsychotic drugs. Biochem Pharmacol. 2017; 143:10–24.

82. Keshavan MS, Lawler AN, Nasrallah HA, Tandon R. New drug developments in psychosis: challenges, opportunities and strategies. Prog Neurobiol. 2017; 152:3–20.

83. van Praag HM. Kraepelin, biological psychiatry, and beyond. Eur Arch Psychiatry Clin Neurosci. 2008; 258:Suppl 2. 29–32.

84. Blashfield RK, Draguns JG. Toward a taxonomy of psychopathology: the purpose of psychiatric classification. Br J Psychiatry. 1976; 129:574–583.

85. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010; 167:748–751.

86. Miller R. Validating concepts of mental disorder: precedents from the history of science. Biol Cybern. 2014; 108:689–699.

87. Esterberg ML, Compton MT. The psychosis continuum and categorical versus dimensional diagnostic approaches. Curr Psychiatry Rep. 2009; 11:179–184.

88. Lilienfeld SO, Treadway MT. Clashing diagnostic approaches: DSM-ICD versus RDoC. Annu Rev Clin Psychol. 2016; 12:435–463.

89. Jaspers K. J Hoenig MW Hamilton . General Psychopathology. Manchester: Manchester University Press;1963.

90. Oyebode F. Sims' Symptoms in the mind: an introduction to descriptive psychopathology. 5th ed. Edinburgh: Saunders Elsevier;2015.